FindTrial
Sign In

Effects of mangiferin supplement on hyperlipidemia population: a randomized controlled trial

Effects of mangiferin supplement on hyperlipidemia population: a randomized controlled trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-13003962
Enrollment
Unknown
Registered
2013-12-05
Start date
2013-12-10
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hyperlipidemia population

Interventions

Placebo:Placebo treatment
mangiferin:mangiferin treatment

Sponsors

Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
35 Years to 65 Years

Inclusion criteria

Inclusion criteria: A history of hyperlipidemia was based on a public hospital laboratory print-out dated within half a year and showing the plasma total cholesterol concentration >/=5.2 mmol/L; triglyceride concentration >/=1.65 mmol/L; aged between 35 and 65 years.

Exclusion criteria

Exclusion criteria: Cardiovascular disease, diabetes mellitus,liver/renal disease and other oral lipid-lowering drug.

Design outcomes

Primary

MeasureTime frame
blood glucose;blood lipids;free fatty acids;liver enzyme;beta-hydroxybutyrate;Lipid metabolism enzymy;—

Countries

China

Contacts

Public ContactSun Changhao

Harbin Medical University

changhaosun2002@163.com+86 0451 87502801

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026